



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

N6-Benzyladenosine

Cat. No.:	HY-N7844
CAS No.:	4294-16-0
Molecular Formula:	C ₁₇ H ₁₉ N ₅ O ₄
Molecular Weight:	357.36
Target:	Apoptosis; Adenosine Receptor
Pathway:	Apoptosis; GPCR/G Protein
Storage:	4°C, protect from light
	* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (349.79 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.7983 mL	13.9915 mL	27.9830 mL
	5 mM		0.5597 mL	2.7983 mL	5.5966 mL
	10 mM		0.2798 mL	1.3991 mL	2.7983 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on *T. gondii* adenosine kinase and glioma^{[1]-[5]}.

In Vitro

N6-benzyladenosine suppresses the clonogenic activity and the growth of different neoplastic cells^[2].
 N6-benzyladenosine results cell morphology alteration and actin cytoskeleton disorganization in T24 cell^[2].
 N6-benzyladenosine (10 μM; 24 h) is a potent inducer of apoptosis, and belongs to apoptotic systems with distinct caspase-3 and caspase-9 activation^[3].
 N6-benzyladenosine (0-100 μM; 24 h) induces chromatin condensation, formation of apoptotic bodies, and cleavage of DNA to nucleosomal fragments in a dose-dependent manner^[3].
 N6-benzyladenosine acts as a selective anti-toxoplasma agent with binding affinity to *T. gondii* adenosine kinase (apparent K_m = 179.8 μM), over human adenosine kinase^[4].
 N6-benzyladenosine (0-50 μM) shows weak inhibition against adenosine kinase deficient (TgAKS3) strains of *Toxoplasma gondii*^[4].
 N6-benzyladenosine (compound 2) (0.3-20 μM) exerts anti-glioma activity by interfering with the mevalonate pathway and inhibiting FPPS (Farnesyl pyrophosphate synthase) ^[5].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[3]

Cell Line:	HL-60
Concentration:	10 μ M
Incubation Time:	24 hours
Result:	Induced cell apoptosis by increasing caspase-3 (DEVDase) as well as caspase-9 (LEHDase) activity, indicating an apoptotic systems with distinct caspase-3/9 activation.

Apoptosis Analysis^[5]

Cell Line:	U87MG human glioma cell line.
Concentration:	0.3, 0.6, 1.2, 2.5, 5, 10, 20 μ M
Incubation Time:	48 hours
Result:	Inhibited glioma growth by interfering with the mevalonate pathway and inhibiting FPPS.

REFERENCES

- [1]. Kaminek M, et al. Cytokinin activities of N6-benzyladenosine derivatives hydroxylated on the side-chain phenyl ring. Journal of Plant Growth Regulation. 1987. 6(2):113.
- [2]. Castiglioni S, et al. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells. Anticancer Agents Med Chem. 2013 May;13(4):672-8.
- [3]. Mlejnek P. Caspase inhibition and N6-benzyladenosine-induced apoptosis in HL-60 cells. J Cell Biochem. 2001;83(4):678-89.
- [4]. Kim YA, et al. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochem Pharmacol. 2007 May 15;73(10):1558-72.
- [5]. Grimaldi M, et al. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity. Bioorg Chem. 2020 May;98:103449.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA